Sign up Australia
Proactive Investors - Run By Investors For Investors

Holista Colltech Ltd and Nadja Piatka to promote low GI white bread

Holista Colltech Ltd and Nadja Piatka to promote low GI white bread

Holista Colltech Ltd (ASX:HCT) and celebrity food expert Nadja Piatka will promote low-GI (glycemic index) foods in North America.

Holista and Nadja Foods have formed a 51-49 joint venture - Holista Foods, which will promote low-GI reducer for white bread and baked products across North America.

Nadja Piatka, a former guest on the Oprah Winfrey show and baked goods supplier to major food chains such as McDonald’s and Subway, will assume the post of CEO at Holista Foods.

Baked goods are the top source of high-GI foods in the modern diet. GI values indicate the rate and level at which different carbohydrate-based foods increase blood glucose and insulin.

The low-GI movement is gaining traction as consumers are getting educated on making healthy food choices and are waiting for products to meet this demand.

According to market research, North America is the world’s largest market for baked goods, estimated at US$37 billion and growing at 2% a year.

In addition to low-GI reducer for baked products, Holista has a suite of other ingredients including low sodium salt, low fat fried foods and low calorie sugar.


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full HCT profile View Profile

Holista Colltech Ltd Timeline

September 19 2017

Related Articles

June 07 2018
Ventripoint received key FDA approval to sell the device with the four-chamber heart analysis last month
Harley Street sign
December 07 2017
The injection will bankroll the continuing technical development of the firm’s first LIGHT system and its installation at the Harley Street Proton Therapy Centre
numerous pills
March 24 2018
Genervon is on the lookout for pharma partners to help advance its GM6 drug, which takes aim at a range of deadly diseases hitting the central nervous system

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use